Fact.MR – A Market Research and Competitive Intelligence Provider: According to a recent Fact.MR market research analysis, the global oral antiviral market is expected to rise at a rapid rate, producing revenue throughout the forecast period.
Branded Oral Antivirals to Acquire Major Chunk of the Oral Antivirals Market
The latest Fact.MR research study offers oral antivirals demand outlook and studies growth opportunities in key segments, including type, drug class, disease indication, and distribution channel. The survey report also reveals key factors affecting the growth of the oral antivirals between 2021 and 2031
Fact.MR – A Market Research and Competitive Intelligence Provider: According to a recent Fact.MR market research analysis, the global oral antiviral market is expected to rise at a rapid rate, producing revenue throughout the forecast period (2021-2031). The demand for oral antivirals has increased as the burden of chronic diseases such as hepatitis, HIV, and coronavirus has increased.
Due to the enormous global outbreak of COVID-19, the market saw an increase in sales. As the number of cases mounted, governments and private healthcare organizations around the world expanded their research and development efforts to find a cure for the novel coronavirus.
The need for oral antivirals has risen tremendously as a result of extensive research activities around the world. In addition, the rising number of HIV diagnoses has boosted sales of oral antivirals. Increased research activity for the development of innovative pharmacological treatments have come from favorable government initiatives focused at reducing the global burden of HIV.
Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=5613
HIV continues to be a global burden and a major health issue, having claimed around 36.3 million lives across the globe so far, stated World Health Organization (WHO) in its latest issue of 2021. According to the UNAIDS, around 45.1 million people were affected with AIDS in 2020.
Besides this, surge in cases of novel coronavirus has compelled governments to increase their efforts in finding the cure of the virus. Countries such as India is still witnessing spike in the cases of COVID-19. So far, there are 220,563,227 confirmed cases across the globe, including 4,565,483 deaths registered as of 5th September 2021, states WHO.
With the number of cases of these chronic diseases on the rise, the government and healthcare institutions are doubling down on their efforts and expanding their research activities in order to discover new oral antiviral treatments. As a result, the market will have significant growth potential.
“Due to surging cases of COVID-19 and HIV, especially in countries such as India and the U.S., demand for oral antivirals have accelerated. On the back of this, preference for branded oral antivirals for the treatment of chronic ailments are creating remunerative growth opportunities for the market players,” says the Fact.MR analyst.
Key Takeaways:
- By type, branded oral antivirals are expected to gain popularity during the forecast period
- By disease indication, hepatitis segment is likely to expand the most, while the coronavirus segment is expected to grow the fastest, owing to an increase in COVID-19 infections, particularly in India.
- Hospital pharmacies are likely to be the dominant distribution channel for oral antivirals, but due to important companies’ increasing shift to online platforms, the online pharmacies segment is expected to rise significantly.
- India is likely to lead the growth of the South Asian oral antivirals market, with considerable research and development initiatives aimed at lowering COVID rates. -19 instances
- Due to the rise of the biologics industry and expanding research and development efforts, China is predicted to be the most profitable country in the East Asia market.
- The United States will emerge as a prospective market for oral antivirals main players, owing to the expansion of healthcare infrastructure and rising demand for biosimilars.
Growth Drivers:
- Oral antiviral sales will benefit from a surge in demand for biosimilars for the treatment of chronic diseases including influenza and coronavirus.
- Market growth will be aided by the high frequency of chronic diseases and the expansion of the biologics market.
- Growing patient pools in home care settings and rising awareness of self-administration will provide profitable growth prospects for the oral antivirals industry.
Key Restraints:
- A lack of understanding and efficacy as a result of oral drug effects, resulting in first-pass metabolism, is likely to stymie growth.
- Increased pricing pressure on important corporations and consumers is anticipated to stifle demand for oral antivirals due to side effects such as body soreness, high fever, nausea, and others.
To learn more about Oral Antivirals Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=5613
Competitive Landscape
Key companies are actively focusing on novel drug development and product launches to expand their product portfolio. Inorganic strategies such as mergers and collaborations are being adopted by key players to stay ahead in the competition.
Leading players are also actively participating in acquisitions of other key companies to increase their market penetration and gain competitive edge in the industry. For instance,
- In March 2021, Pfizer Inc. announced the initiation of its phase 1 study of its novel oral antiviral therapeutic agent against SARS-CoV-2. The trail is being conducted in the U.S. and has demonstrated potent in-vitro anti-viral activity against SARS-CoV-2, virus that causes COVID-19.
- In June 2021, Merck announced its agreement with the U.S. government for molnupiravir (MK-4482). Merck announced that molnupiravir is being evaluated in a Phase 3 clinical trial, MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. The U.S. government is committed to purchase approximately 1.7 million courses of molnupiravir upon issuance and approval by the U.S. Food and Drug Administration (FDA).
- In October 2020, Roche announced its collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients.
Some of the leading oral antivirals providers profiled by Fact.MR are:
- Novartis AG
- Abbvie Inc.
- GlaxoSmithKline
- Merck & Co.Inc.
- Bristol-Myers Squibb Company
- Mylan N.V.
- Gilead Sciences Inc.
- Janssen Pharmaceuticals Inc.
- Appili Therapeutics
- Boston biotech Atea Pharmaceutical
More Valuable Insights on Oral Antivirals Market
Fact.MR, in its new report, offers an unbiased analysis of the global oral antivirals market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in the oral antivirals market with detailed segmentation:
By Type:
- Generic
- Branded
By Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTI)
- Neuraminidase inhibitor
- Nucleoside analogues of guanine
- Nucleoside analogues of thymidine
- Protease Inhibitors
- Nucleotide reverse transcriptase inhibitor (NtRTI)
- Combination Drugs
- Others
By Disease Indication:
- Influenza
- Hepatitis
- Human Immunodeficiency Virus (HIV)
- Coronavirus
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Key Questions Covered in the Oral Antivirals Market Report
- The report offers insight into oral antivirals demand outlook for 2021-2031
- The market survey also highlights projected sales growth for the oral antivirals market between 2021 and 2031
- Oral antivirals market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Oral antivirals market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain –
Respiratory Virus Vaccines Market Forecast - The tightening noose of COVID-19, combined with the discovery of a slew of new respiratory viruses, underscores the need for therapeutic and preventive strategies to be developed. With the current epidemic, demand for respiratory virus vaccinations is projected to increase dramatically.
Drug Discovery Services Market Analysis - The expansion of drug discovery services can be attributed to an increase in research and development efforts and expenditures, as well as leading pharmaceutical companies’ shift to outsourcing. The use of improved technology in the drug discovery process is also a major market growth factor.
Extended Oral Antibiotics Market Scope - Due to the increased number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections, extended oral antibiotics are expected to have substantial demand in the market.
Antibiotic-Associated Diarrhea Treatment Market Analysis - The market for antibiotic-associated diarrhea treatment has grown as a result of the availability of over-the-counter medications, which has contributed to an increase in the prevalence of antibiotic-associated diarrhea.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR